Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.49 and traded as low as $1.15. Evoke Pharma shares last traded at $1.28, with a volume of 26,677 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Evoke Pharma in a research note on Friday. They issued a “sell” rating for the company.
Evoke Pharma Stock Performance
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.56) earnings per share for the quarter. The business had revenue of $1.13 million during the quarter. Evoke Pharma had a negative return on equity of 258.20% and a negative net margin of 222.13%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
- Five stocks we like better than Evoke Pharma
- What is an Earnings Surprise?
- Institutional activity provides a bottom for gaming stocks
- What is Insider Trading? What You Can Learn from Insider Trading
- Coca-Cola EuroPacific Partners is a tasty play on Coke
- Investing in Travel Stocks Benefits
- 3 reasons Qualcomm might be the easiest buy this month
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.